ArticleLeukemia2002
CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells.
Article in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Review
- Integrated single cell multiomic profiling and functional validation reveal distinct cellular routes to human plasma cell differentiation.bioRxiv : the preprint server for biology · 2026Article
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- Survival of Human Bone Marrow Plasma Cells In Vitro Depends on the Support of the Stromal Cells, PI3K, and Canonical NF-kappaB Signaling.European journal of immunology · 2025Article
- Diagnostic and prognostic value of CD44v9 and TIM3 expression in CKOncology letters · 2024Article
- EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress.Blood advances · 2023Article
- Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease.Frontiers in oncology · 2022Review
- Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.Cancers · 2020Review
- The Maintenance of Memory Plasma Cells.Frontiers in immunology · 2019Review
- Quantification of plasma cell dynamics using mathematical modelling.Royal Society open science · 2018Article
- CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression.Frontiers in cell and developmental biology · 2018Review
- Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.Seminars in oncology · 2017Review
- Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.Clinical epigenetics · 2017Review
- Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus.Advanced materials (Deerfield Beach, Fla.) · 2016Article
- Identify multiple myeloma stem cells: Utopia?World journal of stem cells · 2015Review
- Immunophenotyping in multiple myeloma and related plasma cell disorders.Best practice & research. Clinical haematology · 2010Review
- Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells.The American journal of pathology · 2007Article
- Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.Oncogene · 2006Article
- Article
- Identification of proteoglycans as the APRIL-specific binding partners.The Journal of experimental medicine · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of CD44v9-containing isoforms (CD44v9) on myeloma plasma cells correlates with unfavorable prognosis, suggesting that CD44 variant molecules are involved in the disease process. In this study, the presence of CD44v on B cell lines from different stages of development was analyzed by flow cytometry and a role in adhesion to stromal cells from different tissues was evaluated in in vitro binding assays. CD44v3, v6 and v9 isoforms were exclusively expressed on plasma cell lines and CD44v9 expression correlated with IL-6-dependent plasma cell growth. Binding studies using CD44 isoform- specific reagents showed that CD44v6 and CD44v9 were involved in binding to bone marrow stromal cells, but not to in vitro synthesized ECM or hyaluronic acid. CD44v9-mediated plasma cell binding resulted in a significant induction of IL-6 secretion by bone marrow stromal cells. Large differences in quantitative plasma cell binding to stromal cells from different tissues were observed. These, however, could not be related to a differential use of CD44v in these binding processes. The role of CD44v9 in adhesion induced IL-6 secretion and its preferential expression on IL-6-dependent plasma cell lines may explain the previously observed correlation between CD44v9 expression and adverse prognosis in multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.